SUSTAIN research study showed that in patients with type 2 diabetes at high cardiovascular risk, the rate of first occurrence of death from cardiovascular causes, nonfatal heart attack and stroke was significantly lower in those receiving Ozempic compared to those patients receiving placebo
Patients are randomized to pemvidutide 1.2 or 1.8 mg weekly, or placebo for 24 weeks, with primary endpoints of MASH resolution without fibrosis progression and fibrosis amelioration without MASH deterioration
Monitoring your response throughout the cycle is non-negotiable
Real People, Real Stories, Real Glow-Ups Dont just read our website, watch our videos on social media
These aren't just any smoothies
Healthcare providers may also use Ozempic injectables off-label for weight loss management